Quickly following on the approval of single agents, adjuvant immunotherapy combinations are quickly progressing through development, with promising signs of clinical activity seen in phase II studies, according to a presentation by Jeffrey S. Weber, MD, PhD, at the 37th Annual CFS®.
The European Commission has approved nivolumab at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection.
Immunotherapies designed to exploit the host immune system to specifically target cancer cells exploded onto the oncology scene in the mid-1980s, when the first such agents started to show success in melanoma and renal cell carcinoma.
For nearly a decade, immunotherapy and molecularly targeted agents have been the focus of intense development. Now emerging evidence suggests that both modalities can deliver long-term benefits for patients, but the findings may prompt additional questions of how best to fit these transformative therapies into treatment landscapes.
The molecular profile of Merkel cell carcinoma differs depending upon whether the malignancy is driven by ultraviolet light or by a virus and can be correlated with responses to immunotherapy, according to recent study findings.
The treatment landscape changed significantly with the first melanoma clinical trials in 2001, which evaluated the CTLA-4 antibodies ipilimumab (Yervoy) and tremelimumab.
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of nivolumab at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection.
Five melanoma experts discuss findings from several exciting studies presented at the 2019 ASCO Annual Meeting that are helping to change the way patients with malignant melanoma are treated.
A 2018 Giants of Cancer Care® award winner in Melanoma and Other Skin Cancers, Caroline Robert, MD, PhD, has helped clarify the role of immune therapies in advanced melanoma with her groundbreaking work on clinical trials evaluating anti– CTLA-4 and anti–PD-1 antibodies.
Encorafenib (Braftovi) plus binimetinib (Mektovi) had superior overall survival and progression-free survival compared with encorafenib or vemurafenib (Zelboraf) alone in patients with BRAF V600–mutant melanoma.